Evidence map›Paper›PMID 28201868›Full record

ReviewBioconjugate chemistry2017

Enzyme-Responsive Liposomes for the Delivery of Anticancer Drugs.

Farnaz Fouladi, Kristine J Steffen, Sanku Mallik

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Bioconjugate chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 170 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Liposomes in Cancer Therapy: How Did We Start and Where Are We Now.International journal of molecular sciences · 2023
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Farnaz FouladiDepartment of Pharmaceutical Sciences, North Dakota State University , Fargo, North Dakota 58108, United States.
Kristine J SteffenDepartment of Pharmaceutical Sciences, North Dakota State University , Fargo, North Dakota 58108, United States.
Sanku MallikDepartment of Pharmaceutical Sciences, North Dakota State University , Fargo, North Dakota 58108, United States.ORCID http://orcid.org/0000-0003-4236-2512
North Dakota State University · US

Funding

Echogenic Polymersomes for Triggered Contents ReleaseR01GM114080 · NIGMS · NORTH DAKOTA STATE UNIVERSITY · PI MALLIK, SANKU, SARKAR, KAUSIK · 2015 to 2023
$2.6M
NIGMS NIH HHS R01 GM114080
6 · The paper itself

Abstract

Liposomes are nanocarriers that deliver the payloads at the target site, leading to therapeutic drug concentrations at the diseased site and reduced toxic effects in healthy tissues. Several approaches have been used to enhance the ability of the nanocarrier to target the specific tissues, including ligand-targeted liposomes and stimuli-responsive liposomes. Ligand-targeted liposomes exhibit higher uptake by the target tissue due to the targeting ligand attached to the surface, while the stimuli-responsive liposomes do not release their cargo unless they expose to an endogenous or exogenous stimulant at the target site. In this review, we mainly focus on the liposomes that are responsive to pathologically increased levels of enzymes at the target site. Enzyme-responsive liposomes release their cargo upon contact with the enzyme through several destabilization mechanisms: (1) structural perturbation in the lipid bilayer, (2) removal of a shielding polymer from the surface and increased cellular uptake, (3) cleavage of a lipopeptide or lipopolymer incorporated in the bilayer, and (4) activation of a prodrug in the liposomes.

Indexed as

BiocatalysisAnimalsAntineoplastic AgentsCathepsin BDelayed-Action PreparationsDrug Delivery SystemsHumansLipopeptidesLiposomesMatrix MetalloproteinasesNeoplasmsPancreatic ElastasePhospholipases A2, SecretoryPolymersProdrugsProstate-Specific AntigenAntineoplastic AgentsCathepsin BDelayed-Action PreparationsLipopeptidesLiposomesMatrix MetalloproteinasesPancreatic ElastasePhospholipases A2, SecretoryPolymersProdrugsProstate-Specific AntigenUrokinase-Type Plasminogen Activator

Identifiers

PMID28201868
PMCPMC5509414
OpenAlexW2588501081

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.